Once-Daily Pill for FOP Bone Growth in Teens and Adults

Atebrioz is a once-daily oral activin receptor-like kinase 2 (ALK2) inhibitor (zilurgisertib) tablet. On 25 September 2026, FDA approved Atebrioz to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP) (FDA Human Drugs news; Novel Drug Approvals for 2026 row #44). Recommended starting dosage on the FDA announcement: 100 mg orally once daily with or without food. Developed by Incyte; worldwide development and commercialization licensed to Mirum Pharmaceuticals. This is not a cure that removes bone already formed, not surgery, and not interchangeable with other FOP medicines.

Distinct path — not this carton: Pasatru (garetosmab-grts) is an intravenous Activin A monoclonal antibody labelled 19 August 2026 for adults with FOP to reduce new HO lesions and clinician-assessed flare-ups (already covered on Medcelerator). Sohonos (palovarotene) is an oral RARγ-selective retinoid with its own age bands and labels where authorised. Atebrioz is an oral ALK2 small-molecule with a ≥12 years US labelled age band. Compare labels with the FOP clinic; they are not interchangeable.

Where this is taking place

Commercial labelled door today: United States — FDA full approval 25 Sep 2026 for ages 12 and older to reduce volume of total new HO. Company approval materials (Mirum / Incyte, 25 Sep 2026): Atebrioz expected commercially available in the US in October through Mirum Access Plus (MAP) — insurance navigation, financial assistance for eligible patients, and prescription support. MAP phone on company materials: 1-855-MRM-4YOU (1-855-676-4968); program site mirumaccessplus.com. “As little as $0 per month” language is company financial-assistance framing, not a formulary guarantee and not a price in this article.

Outside the United States: As of this draft, Health Canada, EMA/EC, MHRA, TGA, PMDA/MHLW, Swissmedic, and NMPA authorisation for Atebrioz / zilurgisertib not confirmed on sources used here. Company materials: an EMA marketing-authorisation application is under review (supported by PROGRESS Cohort 1) — MAA under review ≠ EC licence. A US bottle is not another country’s label. Do not import on your own.

PROGRESS — NCT05090891 (FDA effectiveness source): Phase 2, randomized, double-blind, placebo-controlled. Lead sponsor on ClinicalTrials.gov: Incyte Corporation. CT.gov status at retrieval: recruiting (pediatric cohorts continue; Cohort 1 ages ≥12 completed the pivotal double-blind period used for the label conversation). Cohort 1: 63 patients ≥12 years, randomized to zilurgisertib 100 mg or placebo once daily for 24 weeks, then open-label extension (additional 292 weeks on the FDA announcement / protocol framing). Sites include the United States (e.g. Mayo Clinic Rochester, Children’s Hospital of Philadelphia) plus sites in Argentina, Australia, Brazil, Canada (University Health Network Toronto — trial site ≠ Health Canada licence), Chile, China, and other countries listed on CT.gov. Younger cohorts: Cohort 2 (ages 6 to <12) enrollment completed per company; Cohort 3 (ages 2 to <12) enrollment underway — not the commercial ≥12 labelled door.

The practical US door is an FOP-experienced clinician (often metabolic bone / endocrinology / rare-disease centre) who can confirm FOP, prescribe Atebrioz when stocked, manage pregnancy prevention where needed, and watch drug interactions — not a mail-order experiment.

Approval matrix

Access by country

• United States: Ask an FOP / metabolic bone / rare-disease clinic about labelled Atebrioz if the person is ≥12 years with FOP and the goal is reducing new HO volume. Path: confirm diagnosis → review contraception / pregnancy risk and interacting medicines → prescribe 100 mg once daily when US commercial supply is available → enroll in Mirum Access Plus if the clinic uses that channel (1-855-676-4968). AE / product questions: follow the USPI / Medication Guide when posted; FDA MedWatch 1-800-FDA-1088. No list price or copay dollars in this article.
• Canada / EU / UK / Australia / Japan / other countries: Authorisation not confirmed here. Ask the local FOP clinician what legal paths exist (documented special-access / named-patient rules, referral to a labelled-country centre, or open pediatric PROGRESS cohorts when eligible) — without treating a US bottle as a foreign carton.
• If your regulator has not authorised it: do not import on your own.

Who is eligible

United States (from FDA Human Drugs announcement 25 Sep 2026 — confirm full USPI with the clinic when posted):

• Indication: Reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP).
• Dose (FDA news): 100 mg orally once daily, with or without food.
• Pregnancy: Can cause fetal harm (animal data). Patients of reproductive potential should use effective contraception; discontinue immediately and contact the clinician if pregnancy occurs.
• Common side effects named on FDA news: headache, joint pain, upper respiratory tract infection, nosebleeds, nausea. Should not be taken with certain other medications (see label).
• Younger than 12: Commercial label is ≥12. PROGRESS Cohorts 2–3 are research paths for younger children — not the commercial carton.

Not labelled on sources confirmed for this draft:

• Children under 12 as a commercial population.
• EU, UK, Canadian, Japanese, Australian, Swiss, or Chinese Atebrioz marketing authorisations.
• Replacing Pasatru or Sohonos by self-switching without a clinician reading each label.

What the pivotal study showed (PROGRESS Cohort 1 / NCT05090891)

Use the FDA announcement numbers for the US prescription conversation until the full USPI table is posted; journals and company decks are supportive reading.

• Randomized, double-blind, placebo-controlled; 63 patients with FOP assigned to Atebrioz 100 mg or placebo once daily for 24 weeks, then open-label extension.
• Efficacy basis (FDA): change from baseline in volume of total new heterotopic ossification vs placebo in the double-blind period, assessed by whole-body CT.
• At Week 24 (FDA): Atebrioz group average 3.2 cm³ decrease in volume of total new HO; placebo group average 24.6 cm³ increase.
• Company materials: treatment effects maintained through Week 48 of the open-label extension (company framing — align with USPI when available).
• Company safety framing for the double-blind period: generally well tolerated; most AEs mild/moderate; no discontinuations or dose reductions attributed to AEs in that company summary — still use the label for clinical decisions.

Trial status honesty: Cohort 1 supports the ≥12 commercial label. CT.gov remains recruiting because younger cohorts continue — that is not an automatic walk-in door for every newly labelled commercial starter outside US distribution.

How it is taken

Full tablet strengths, NDCs, titration, missed-dose rules, and interaction tables: confirm on the USPI when Drugs@FDA / DailyMed posts the label (not retrieved for this draft).

Safety (what the FDA announcement puts first)

• Fetal harm — contraception for people who can become pregnant; stop and call the clinician if pregnancy occurs.
• Drug interactions — “should not be taken with certain other medications, as described in the label.”
• Common AEs: headache, arthralgia / joint pain, upper respiratory tract infection, epistaxis / nosebleeds, nausea.

How to talk to a doctor

Bring: confirmed FOP diagnosis (and genetic report if you have one), age (≥12 for this carton), current medicines (for interaction check), pregnancy / contraception plans, and whether the person is already on Pasatru, Sohonos, or a trial. Ask: “Am I / is my child in the FDA-labelled Atebrioz population, and how does an oral ALK2 inhibitor compare with Pasatru or Sohonos for this person?” Ask how Mirum Access Plus fits their clinic’s ordering path when US supply starts. Do not start, stop, or combine FOP medicines without the clinic.

Research and regulatory team

• Lead investigator named on Mirum/Incyte approval materials: Robert Pignolo, M.D., Ph.D., Mayo Clinic College of Medicine (PROGRESS).
• PROGRESS sponsor (CT.gov): Incyte Corporation.
• US commercial licence holder (company): Mirum Pharmaceuticals, Inc. (licensed from Incyte).
• Patient community organisation quoted on company materials: IFOPA (International Fibrodysplasia Ossificans Progressiva Association) — organisational voice, not a prescribing clinic.
• FDA designations (FDA news): Fast Track, Priority Review, Orphan Drug. Company: Rare Pediatric Disease Priority Review Voucher issued to Incyte.

Canada zoom: trial site is not a licence

PROGRESS lists University Health Network Toronto General Hospital among sites. A Canadian trial site or completed visit is not a Health Canada Notice of Compliance for Atebrioz. Atebrioz authorisation not confirmed in Canada on sources used here. Ask the Canadian FOP clinic what legal options exist while there is no Canadian Atebrioz label. Do not import a US bottle on your own.

Bottom line

Atebrioz is a US-labelled once-daily oral ALK2 inhibitor for people 12 and older with FOP to reduce new HO volume, approved 25 September 2026. It is a different door from Pasatru (monthly IV, adults) and from Sohonos. The near-term path is an FOP clinic prescription when US commercial supply and Mirum Access Plus logistics are live — not a DIY import, and not an assumption that every country or plan will fund it.

Primary sources

• FDA: FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva (25 Sep 2026)
• FDA: Novel Drug Approvals for 2026 (row #44 Atebrioz)
• ClinicalTrials.gov: NCT05090891 — PROGRESS
• Company (labeled company, not regulator): Mirum / Incyte FDA approval announcement (25 Sep 2026) — MAP / October availability framing